[1] |
Lin NU,Vanderplas A,Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network[J]. Cancer, 2012, 118(22):5463-5472.
|
[2] |
Tischkowitz M,Brunet JS,Bégin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer [J]. BMC Cancer, 2007,7: 134.
|
[3] |
Dent R,Trudeau M,Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence [J]. Clin Cancer Res,2007, 13(15 Pt 1):4429-4434.
|
[4] |
Harris LN,Broadwater G,Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 [J]. Breast Cancer Res,2006,8(6): R66.
|
[5] |
Fisher B,Bryant J,Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J]. J Clin Oncol, 1998,16(8): 2672-2685.
|
[6] |
Wolmark N,Wang J,Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 [J]. J Natl Cancer Inst Monogr, 2001, 30: 96-102.
|
[7] |
von Minckwitz G,Martin M. Neoadjuvant treatments for triple-negative breast cancer (TNBC) [J]. Ann Oncol, 2012, 23 Suppl 6:vi35-39.
|
[8] |
Liedtke C,Mazouni C,Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J]. J Clin Oncol, 2008, 26(8):1275-1281.
|
[9] |
Carey LA,Dees EC,Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes [J]. Clin Cancer Res, 2007, 13(8):2329-2334.
|
[10] |
Cortazar P,Zhang L,Untch M, et al.Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938):164-172.
|
[11] |
von Minckwitz G,Untch M,Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes [J]. J Clin Oncol, 2012, 30(15):1796-1804.
|
[12] |
Kennedy CR,Gao F,Margenthaler JA. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer [J]. J Surg Res, 2010,163(1): 52-57.
|
[13] |
Fisher CS,Ma CX,Gillanders WE, et al. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response [J]. Ann Surg Oncol, 2012, 19(1): 253-258.
|
[14] |
Hammond ME,Hayes DF,Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) [J]. Arch Pathol Lab Med, 2010, 134(7):e48-e72.
|
[15] |
Ferrière JP,Assier I,Curé H, et al. Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome [J]. Am J Clin Oncol, 1998, 21(2):117-120.
|
[16] |
Machiavelli MR,Romero AO,Pérez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma [J]. Cancer J Sci Am, 1998,4(2):125-131.
|
[17] |
Rastogi P,Anderson SJ,Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J]. J Clin Oncol,2008, 26(5): 778-785.
|
[18] |
Shao Z,Chaudhri S,Guo M, et al. Neoadjuvant chemotherapy in triple negative breast cancer: an observational study [J]. Oncol Res, 2016, 23(6): 291-302.
|